Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)
NCT05000216Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Viral Vectors, Lipid-based Nanoparticles, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of elasomeran, tozinameran, Ad26.COV2.S, monovalent [B.1.351] CoV2 preS dTM-AS03, elasomeran + imelasomeran in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2021; status: terminated.
02
Drugs
elasomerantozinameranAd26.COV2.Smonovalent [B.1.351] CoV2 preS dTM-AS03elasomeran + imelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05000216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000216.